Saiph Capital LLC Buys 657 Shares of Gilead Sciences, Inc. (NASDAQ:GILD)

Saiph Capital LLC boosted its stake in Gilead Sciences, Inc. (NASDAQ:GILD) by 13.3% in the fourth quarter, HoldingsChannel reports. The firm owned 5,591 shares of the biopharmaceutical company’s stock after acquiring an additional 657 shares during the period. Saiph Capital LLC’s holdings in Gilead Sciences were worth $516,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also added to or reduced their stakes in GILD. OVERSEA CHINESE BANKING Corp Ltd acquired a new position in Gilead Sciences during the fourth quarter valued at approximately $670,000. Intech Investment Management LLC boosted its position in Gilead Sciences by 1.6% during the fourth quarter. Intech Investment Management LLC now owns 195,587 shares of the biopharmaceutical company’s stock valued at $18,066,000 after purchasing an additional 3,038 shares during the last quarter. PDS Planning Inc boosted its position in Gilead Sciences by 3.8% during the fourth quarter. PDS Planning Inc now owns 4,670 shares of the biopharmaceutical company’s stock valued at $431,000 after purchasing an additional 170 shares during the last quarter. Haven Capital Group Inc. acquired a new stake in shares of Gilead Sciences in the fourth quarter valued at approximately $427,000. Finally, Argent Advisors Inc. lifted its position in shares of Gilead Sciences by 1.3% in the fourth quarter. Argent Advisors Inc. now owns 11,345 shares of the biopharmaceutical company’s stock valued at $1,048,000 after buying an additional 142 shares during the last quarter. Institutional investors own 83.67% of the company’s stock.

Gilead Sciences Trading Down 1.8 %

Shares of GILD opened at $110.23 on Wednesday. Gilead Sciences, Inc. has a 52-week low of $62.07 and a 52-week high of $119.96. The business’s fifty day moving average is $102.63 and its 200-day moving average is $93.38. The company has a debt-to-equity ratio of 1.24, a quick ratio of 1.20 and a current ratio of 1.50. The firm has a market cap of $137.27 billion, a price-to-earnings ratio of 297.92, a PEG ratio of 0.71 and a beta of 0.21.

Gilead Sciences (NASDAQ:GILD) last issued its quarterly earnings results on Tuesday, February 11th. The biopharmaceutical company reported $1.90 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.67 by $0.23. Gilead Sciences had a return on equity of 31.63% and a net margin of 1.67%. Equities analysts anticipate that Gilead Sciences, Inc. will post 7.95 EPS for the current fiscal year.

Gilead Sciences Increases Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Friday, March 28th. Investors of record on Friday, March 14th will be issued a dividend of $0.79 per share. This is an increase from Gilead Sciences’s previous quarterly dividend of $0.77. The ex-dividend date is Friday, March 14th. This represents a $3.16 annualized dividend and a dividend yield of 2.87%. Gilead Sciences’s dividend payout ratio (DPR) is 854.05%.

Insider Activity at Gilead Sciences

In related news, CFO Andrew D. Dickinson sold 142,180 shares of the firm’s stock in a transaction on Friday, January 31st. The stock was sold at an average price of $97.22, for a total transaction of $13,822,739.60. Following the sale, the chief financial officer now owns 129,873 shares of the company’s stock, valued at $12,626,253.06. This trade represents a 52.26 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Insiders have sold a total of 302,785 shares of company stock valued at $30,503,250 in the last 90 days. 0.29% of the stock is owned by corporate insiders.

Analyst Ratings Changes

A number of research firms have recently issued reports on GILD. UBS Group raised their price objective on Gilead Sciences from $70.00 to $96.00 and gave the company a “neutral” rating in a research report on Thursday, November 21st. Needham & Company LLC reaffirmed a “hold” rating on shares of Gilead Sciences in a research report on Wednesday, February 12th. Deutsche Bank Aktiengesellschaft raised Gilead Sciences from a “hold” rating to a “buy” rating and raised their price objective for the company from $80.00 to $120.00 in a research report on Tuesday, February 18th. Wells Fargo & Company raised their price objective on Gilead Sciences from $120.00 to $140.00 and gave the company an “overweight” rating in a research report on Wednesday, March 5th. Finally, DZ Bank upgraded Gilead Sciences from a “hold” rating to a “buy” rating and set a $108.00 target price on the stock in a research note on Thursday, February 13th. Eleven research analysts have rated the stock with a hold rating, fifteen have given a buy rating and four have issued a strong buy rating to the stock. According to MarketBeat, Gilead Sciences presently has an average rating of “Moderate Buy” and an average price target of $104.52.

Gilead Sciences Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.